Related Experiment Video
Updated: May 28, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients
Lesley S Park1, Janet P Tate, Amy C Justice
1Yale School of Medicine, West Haven, CT 06516, USA. lesley.park@yale.edu
Insights
The FIB-4 index, calculated from routine lab tests, is a strong predictor of hepatocellular carcinoma (HCC) in HIV-infected individuals. High FIB-4 scores significantly increase HCC risk, aiding in early identification of high-risk patients.
Area of Science:
- Hepatology
- Infectious Diseases
- Oncology
Background:
- Chronic inflammation from viral hepatitis or alcohol use can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
- The FIB-4 index, derived from platelet count, AST, ALT, and age, is a noninvasive marker for liver fibrosis and cirrhosis.
- HIV-infected individuals face elevated risks for viral hepatitis, alcohol-related liver disease, and potentially HCC.
Purpose of the Study:
- To investigate the association between the FIB-4 index and the development of HCC in a large cohort of HIV-infected men.
- To determine if FIB-4 is an independent predictor of HCC in this high-risk population.
Main Methods:
- Utilized proportional hazards models to analyze data from 22,980 HIV-infected men in the Veterans Aging Cohort Study.
- Identified incident HCC cases using the Veterans Affairs Central Cancer Registry.
Main Results:
- 112 incident HCC cases were diagnosed during the study period.
- High FIB-4 scores were strongly associated with increased HCC risk (multivariate-adjusted HR: 9.6; 95% CI, 5.2-17.4 for high FIB-4).
- FIB-4 remained a significant, independent predictor of HCC after adjusting for clinical factors like viral load, CD4 count, and comorbidities.
Conclusions:
- The FIB-4 index is a robust, independent predictor of HCC in HIV-infected patients.
- FIB-4 offers a valuable, easily accessible tool for identifying individuals at high risk of developing HCC, even before clinical signs of cirrhosis appear.
Background:
Chronic inflammation caused by hepatitis B virus infection, hepatitis C virus infection, and/or heavy alcohol use can lead to fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). FIB-4 is an index score calculated from platelet count, alanine transaminase, aspartate transaminase, and age that predicts fibrosis and cirrhosis. We hypothesized that high FIB-4 would be associated with development of HCC in HIV-infected persons, who are at high risk due to high prevalence of viral hepatitis and alcohol consumption, and possibly due to HIV infection itself.
Methods:
Using proportional hazards models, we tested this hypothesis among 22,980 HIV-infected men from the Veterans Aging Cohort Study. We identified incident HCC cases from the Veterans Affairs Central Cancer Registry.
Results:
During follow-up, there were 112 incident HCC diagnoses. The age- and race/ethnic group-adjusted HR was 4.2 [95% confidence interval (CI), 2.4-7.4] for intermediate FIB-4 and 13.0 (95% CI, 7.2-23.4) for high FIB-4, compared with low FIB-4. After further adjustment for enrollment year, CD4 count, HIV-1 RNA level, antiretroviral therapy use, hepatitis B and C virus infection, alcohol abuse/dependency, and diabetes, FIB-4 remained a strong, significant, independent risk factor for HCC. The multivariate-adjusted HR was 3.6 (95% CI, 2.1-6.4) for intermediate FIB-4 and 9.6 (95% CI, 5.2-17.4) for high FIB-4.
Conclusions:
Calculated from routine, noninvasive laboratory tests, FIB-4 is a strong, independent HCC risk factor in HIV-infected patients.
Impact:
FIB-4 might prove valuable as an easily measured index to identify those at highest risk for HCC, even prior to development of clinical cirrhosis.
Related Concept Videos
Hepatitis
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can exist in...
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Viral Hepatitis I: Introduction
